Thursday, June 18, 2026

Policy

Policy•Fierce Biotech•Jun 18, 2026

F2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test

background ▾

• •F2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test

→ Read original article

Policy•Fierce Biotech•Jun 17, 2026

'Biopharma ecosystem is back to full health,' fueled by M&A: PwC

background ▾

• •'Biopharma ecosystem is back to full health,' fueled by M&A: PwC

→ Read original article

Policy•Fierce Biotech•Jun 17, 2026

Jazz, AbCellera strike TCE discovery and development deal worth up to $820M per drug

background ▾

• •Jazz, AbCellera strike TCE discovery and development deal worth up to $820M per drug

→ Read original article

Policy•STAT News•Jun 18, 2026

New infant botulism outbreak puts fancy formulas under scrutiny

background ▾

• •New infant botulism outbreak puts fancy formulas under scrutiny

→ Read original article

Policy•Fierce Biotech•Jun 17, 2026

Vedana Therapeutics surfaces with $46M to develop next generation of migraine prevention therapies

background ▾

• •Vedana Therapeutics surfaces with $46M to develop next generation of migraine prevention therapies

→ Read original article

Market Access

No articles for this category on this date.

Clinical Trials

No articles for this category on this date.